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A ME THOll OF DETECTING VIRAL CONTAr~I!JA TI !HJ IN PARENTERAL SOLUTIONS 
Abstract of Diss ertation 
Th~ pres~nce of contaminants in parenteral sol~tions is 
a constant nemesis against whic h pharmaceutical manufacturers, 
as well as medical, pharmacy , and nursing practitioners mus t 
vigilantly struggle to prov i de quality healt h care. At each 
level in the parenteral drug delivery system, contamination 
is possibl~ bc(ore the patient actually receives the infusion. 
The imple~entation of better practices and procedures conti n ues 
in the que s t of conta minan t-free parenterals. ~ e vertheless , the 
literature is replete with articles documenting contamination of 
parenteral ~edication . 
foreign body particulate matter has been found sequestered 
in the lungs of patients who have received intravenous therapy. 
The entrap~ent of forei~n bodies can occur in other body organs 
besides the lungs. The hazardous effects of this partic ~ late 
matter has been the subject of much concern. Other forms of 
parenteral contaminants have been reported in the liter~ture. 
These include both bacterial and fu"gal contaminants. 
Contaminant detection in parenteral solutions has been 
r.ccompli511ed by several methods . Thes e have included: visua l 
inspection , nephe lometric methods , methods of me~brane 
filtrati on with suhsequent microscopic examination, and methods 
emplbyin~ various electronic adaptatibns . 
No references have been published describing vi ral 
contamination of pnrenterals or r.1e t hods for viral det2ction 
in parenteral sol~tiuns . Yet, viral contaminants infused directly 
into the blood of a pa tient May be of grave clinical sig nifican ce . 
Thus, the objective of thi5 project was to develop a met~oj for 
detecting the presence of vir~sus in small and bulk pare nt. cr<Jl 
solutions. 
Both s mall and large volumes of Sodium Chl oride Inj~ction 
U.S . P. and S percent Dextrose Injection U. S .P . were i noculated 
~ith 100 I.U . or 1 I. U. of Tcbaccq ~1q?aic Virus (TMV) per ml 
of solution . The contents of these parenterals were concen trated 
to a retentate vo!une using molecular filtra~ion . The retentate 
volume was examined for viral content using transmiss i on electron 
microscopy with negative staining techni~ues . 
Efficacy was determined by comparison of the results of 
the contaminated controls wit h the contaminated test groups . 
Statistically significa"t differences we re observed between 
the co"trol yroups, wnich were not ~ubjected to t he test met hod , 
and the t est uroups for bot h s mall and large volume ' parenteral 
solutions . 
Efficiency, which denotes the viral conta~ination l P. vel 
at which viruses are detectable, was determined by comp~ring the 
control groups of uncontaminated p a rentera l sol utio ns wit h 
conta~lnated test gr~up~ of the same solutions . Both gruu ps 
were subjected to the •est r.1ethodology . The control and the test 
groups showed stat i~tic a lly significant differences 3t t he 100 
and the 1 I. li. TrW contaninntion levels . 
The results s howed thnt the defined ~etnod of viral detection 
i s ef ficacious and efficient at t he t ested TMV contamin<Jtio n 
levels . This method could probably be applied to the detection 
of other viral contaminants of p a renteral solutions as well as to 
bio l ogica l viral analys ~s methods . 
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The presence of contaminants in parenteral solutions is 
a constant nemesis against which pharmaceutical manufacturers, 
as well as medical, pharmacy, and nursing practi.cioners must 
vigilantly struggle to provide quality health care. At each 
level in the parenteral drug delivery system, contamination 
is possible before the patient actually receives the infu-
sion therapy. Through contemporary and future science and 
technology, the implementation of better practices and pro-
cedures c:ontinues in the quest of contaminar1t-free paren-
terals. Nonetheless, the literature is replete with articles 
documenting contamination of parenteral medication. 
The objective of this research project is to supplement 
the quality control procedures for parenteral infusions with 
a method capable of detecting viral contaminants in small 
and large volume parenterals. 
1 
LI'fERATURE 
Contaminants in Parenterals 
ln 1949, Von Glahn and Hall ( 8) reported pulmonary em--
boli of cotton fibers which resulted from intravenous injec-
tion of fluids containing cotton fibers. At autopsy char-
acteristic. mononuclear infiltrates and multinucleated giant 
cells were found at the intimal sites of the foreign body 
lodgement. These incidental findings were corroborated by 
Konwaler's (9) report of pulmonary foreign body granuloma 
in autopsi.ed cases hav.i.ng received intravE>nous therapy. 
Subsequent artic.les appeared in the literature describ-
ing pulmonery arteri~l response to foreign bodies associated 
with intravenous therapy (13,14). Confirmatory experimental 
studies using animals were also conducted (27,28). 
As shown by Lie bow et al. ( 62) and Hales ( 61) arterio-
venous shunts in the. lung exist. When these are present, 
particulate contaminants of intravenous fluids may be 
delivered to the general circulation and then be sequestered 
in other body organs besides the lungs (26). 
The impelling study of large volume parenteral contami-
nants originated in 1963 with the work of Garvan and Gun-
ner (1). These authors in their original article and sub-




intravenous fluids, the nature and origin of the contaminants, 
methods of particulate detection, the harmful effects of 
particulate contaminated intravenous fluids both in animal 
exper·imen ts and patients, and compendial recommendations 
for particulate detection, limits, and parenteral fluid 
manufacturing. 
Resulting from the interest generated by the works of 
Garvan and Gunner, in July of l966·the Federal Food and 
Drug Administration convened a Scientific Symposium on Large 
Volume Parenteral Solutions (64). The bas:Lc purposes of the 
symposium were to explore: the problems of parenteral solu-
tions, the health significance of particulate matter, and 
the methods of minimiz:Lng intravenous flu:Ld hea.lth hazards. 
At this symposium, the find:Lngs of vartous authors (l-·3, 
10,13,14,27,28) were presented as evidence of l1azardous 
effects associated with parenteral flutds. Jonas (12) 
described the potentially hazardous effects of introducing 
particulate matter into the vascular system. He stated that 
the effects of the injected particulate matter depend on 
three main factors: 
1. the size, shape, and chemical characteristics 
of the particle, 
2. the site of occlm;ion a.11d degree of interruption 
of blood supply, and 
3. the host response to the particle. 
Included in the host response is the antigenic potential of 




medical significance of particulate matter including inor-
ganic particles, bacteria, and molds. Gross and Carter (5) 
described the pathogenic hazard of particulates in intra-
venous solutions causing pulmonary granulomatous inflammation. 
They stated that the medical significance of the particulate 
matter "rests essentially in a consideration of the state of 
patients receiving large amounts of parenteral :fluids" and 
that recumbent states and concomitant therapy especially with 
large doses of corticosteroids are factors which influence 
the pathogenicity of contaminated infusions. Gross (7) in 
a subsequent article described the possibility of pulmonary 
arteriovenous shunts enabling particulate matter to obstruct 
systemic circulation causing diminished blood supply to 
vital organs. 
Endicott et al. (10) in the symposium's proceedings 
related the significance, source, measurement, and elimina-
tion of particulate matter at the manufacturing level. 
Yakowitz (11) described the problems associated with the 
manufacture, storage, and use of large volume parenterals. 
This symposium further stimulated interest in contami-
nants of large volume parenterals. Turco, Davis, and 
Sivelly (4) have quantitatively studied particulate matter 
in large volume parenterals with and without additives using 
a membrane fiJ.tratl.on technique. They found that both addi-
tives and administration sets increased the number of par-
ticulates in intravenous solutions. These authors further 
5 
described the work of past investigators and related the 
use of a final filter set for removing particulate matter. 
Turco and Davis (15) presented a thorough review of 
the literature on the clinical significance of particulate 
matter. Turco (33) has also described the hazards associ-
ated with parenteral therapy including microbial, pyrogenic, 
and other forms of particula~e contamination in parenteral 
therapy. 
The presence· of particulate matter has been reported in 
commercial antibiotic injectables (23,24,29,30). Rebagay 
~t al. (23) have proposed that the residues in antibiotic 
preparations might react with tissue ~roteins and cause or 
contribute to phlebitis. Stewart (73) found traces of 
macromolecula r proteins of peptide complexes in natural 
cephalosporins and penicillins which possessed allergenic 
potential . Thus, this type of particulate contaminant may 
elici.t host immune response. 
The cli.nical significance of particulate matter wa.s also 
related in the Canadian Journal of Hospital Pharmacy (59). 
Duma has recently described the hazards of intravenous 
therapy in the New England Journal of Medicine (22) and has 
previously reported on particulate matter in the Annals of 
Internal Me d.:i. cin~ ( 65) . It is evident from the widespread 
literature reports that contaminated parenterals are now of 
unquestioned clinical concern. 
Past works have describe d the possibility of microbial 
and fungal contamination of parenterals (6,33) . Numerous 
6 
reports now document the possibility of bact e rial as well 
as mycelial contamination and some have proposed recommenda-
tions as to surveillance of contaminated large volume 
parente rals (19,20,21,35,36,38,39,51-55,58,60). Duma et al. 
(60) cite cases of nosocomial septicemia from intravenous 
fluids and volume-control sets. Guynn et al. ( 35) found that 
5 percent Dextrose Injection U.S.P. was the most hostile to 
bacterial growth, whereas Sodium· Chloride Inj ect i on U.S.P., 
Lactated Ringer's Injection U.S.P., and 5 pe rcen t dextrose 
in Lactate d Ringer's Injection we r e more conduc i ve to bac-
terial growth. They found that gram-negative bacilli pre-
dominat e over gram-positive cocci. as fhe study of Duma et al. 
(60) ha d a l s o indicated . . In the work of Poretz et al . (20) 
most species of organisms isolated were commonly considered 
lacking virulence. Yet, these same organisms may be patho-
genic in the debilitated , · hospitalize d patient. Furthermore, 
the elaboration of endotoxins by gram-negative bacilli 
presents anothe r distinct threat to the patient from contami-
nated parenteral fluids . Wilkinson et al. (52) as well as 
Curry and Quie (63) have shown the preponderance and prolif-
era tion of Can.~ida al_bicans in pare nte ral hyperalimentat ion 
solutions. Deeb and Natsios (58) stated that contamination 
of ''in use " hypera.limenta tion fluids by Candida species 
occurs to an extent greater than 25 pe rcent. 
In 1971, the clinica l significance of contaminated 
large volume parente ral s was sadly r ealized. Ove r 50 patients 
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died as a result of infectioGs which they received from con-
taminated screw-cap infusions (37,50). Resulting from this 
tragedy, the United States Pharmacopeial Convention, funded 
by the Feders_l Food and Drug Administration, organized the 
Natl.onal Coordl.nating Comml.ttee on Large Volume Parenterals. 
Barker ( 45 ), project dl.rector and chairman of the Committee, 
has stated the Committee's purpose is to study the problems 
associated wl.th large volume parenterals and coordinate 
efforts of the member organizations in deall.ng wj.th these 
problems. Activity coordination, guidelines for problem 
identification, recommendations, and increased awareness of 
usage standards have resulted from the committee's endeavors 
(31,37,41,44,45,50). 
Included in a recent report of the National Coordinating 
Committee on Large Volume Parenterals ( 4·1), it is recommended 
that an inline particulate matter retentive final filter be 
serl.ously eonsidered as a requirement for the administration 
of large volume parenterals. Thl.s recommendatl.on is based 
upon numerous studies and their conclusions as to the overall 
advantages of inline final filtratl.on (16,17,32,34,38-40,42, 
55,66,110,123). Some of the advantages arising from the use 
of inline filtration ·as reported in the above studies 
include: 
1. the effective removal of particulate matter 
and resultant reduction of patient risk from 
these contaminants, 
2. the decrease in microbial and pyrogenic con-
tamination, and 
3. the decrease in the incidence of phl.ebitis. 
Some of the disadvantages of inline filters are: 
1 . reduced infusion flow rates especially with 
the 0.22 micrometer (pm) filters, 
2. air entrapment in the filters stopping flow, 
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3. non-bacterial retentioP capabilities of filters 
used other than the 0.22 ~m filters (38), and 
4. the bothersome yet effective clogging of inline 
filters with particulate matter . 
These inherent disadvantages can be overcome by the use of 
an air-venting, ·0.22 ~m inline filter with a large filtration 
surface as reported by Rapp et a l. (42). 
Contaminant Detect ion in Parente rals 
The detect ion of particulate matter ~as been accomplished 
by several me~hods which are either nondestructive or destruc-
tive in nature (l-3,10,18,23,24, 29 ,30,43, 46 ,47,56,57,67). 
Visual inspection unde r diffuse light has been used by 
manufacturers (56,57) and in hospital pharmacy admixture 
prog rams . This nondestruc tive met hod i s subject i ve , qualita-
tive not quantitative, and restricte d to visualization of 
particles greater than 50 ~m (56,57). Bla nchard et al. (43) 
fohnd this method inadequat e for monitoring particulate 
matter in large volume pare ntera ls. 
Nephelometric methods use th~ Tyndall effect of visual 
examination by the light scattering potential of particulates 
in a bea m of light. Particulate detection is depe nde nt on 
the si~e of the contaminant and the angle of scatter. 
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Particles over one ~m can be detected (56,57). This nonde-
structive method provides qualitative comparison solution to 
solution. The method cannot distinguish types of particulate 
matte:o:- and is not quantitative.. Garvan and Gunner (l-3) and 
others (67) have described its use. 
Membrane filtration and subsequent microscopic examina-
tion is a destructive technique which has been used by 
numerous investigators (1·-3,29,30,43,57). This method pro-
vides a permanent record of particulate contamination and 
can provide both qualitative and quantitative comparisons. 
The method can be tedious and particles with refractive 
indices similar to the filter can go ~ndetected. With the 
light microscope particles of 0.2 ~m size can be resolved (68). 
This method has been adopted by the United States Pharma-· 
copeia for particulate matter determination in large volume 
injections for single-dose infusion (72). 
The Coulter Countera has been used for the indirect 
determination of particulate matter in parenteral infusions 
(56,69,110). This method is classed as a destructive tech-
nique for particulate detection. It is a rapid, nonvisual 
method using the principle of changes in electrical resis-
tance caused by particulate matter in an electrically con-
ductive solution. Vessey and Kendall (56) recorded parti-
cles as small as 2.0 ~m, yet it is possible to detect 
aCoulter Electronics, Hialeah, FL. 
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particles less than this size (10). The Coulter Counter can 
be directly us~d for electrolyte solutions only. 
The Royco Liquid Countera is another instrument which 
has been successfully applied to particulate determination in 
injectable solutions (10,57,70). It is bei~g used at the 
manufacturing level (70). As a batch · sampler this instrument 
is categorized as providing a destructive me thod of indirect 
determination uf particulates. The principle of operation 
is that of incident light scattering by contaminant particles 
in a flowing stream of the solution. Thus, it is similar to 
nephelometric methods , but the ~ecrease in li ght r esulting 
from a particJ.e's presence is actually measured by a light 
sensing cell and amplified to produce a characteristic 
pulse height (7Q). It provides a rapid means .of particle 
detection for both e l ectrolyte and non-elect rolyt e s olu-
tions (10,57). It is capable of detecting particles as small 
as two ~m (70). 
The Millipore TT MC Part icle Measurement Computer 
Systemb is an electronically automated adaptation of the 
membrane filtration and microscopic examination technique 
(57 ~71). The parenteral solution is fi ltered through a 
membrane filter. The filter with the collected particulate 
matt e r is then examined by a microscope connected to a 
a 
bRoyco Instruments, Menlo Park, CA 
Millipore Corporation, Bedford, MA 
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television camera. The image of the particulate i s processed 
by a computer JTIOdule a nd displayed on a television monitor 
(71) . As Lim et al. (57) have reported, this system "was 
more prec i se in detection and sizing of particles and more 
rapid in counting of particles than the microscop ic manua l 
examination method." The system is capable of measuring 
entire fields of particles or selective individual particles, 
counting entire fi e lds , computing total area and average are a 
of particulates , computing partiele size distributions and 
other parameters (71). The resolution limit o f the TT MC 
system i s 0.2 ~m, the limit of the optical microscope . (68, 
71). 
Another i ns trument for the analysis of particu l ate mat~ 
t er in large volume parenterals i s the Pro'totr~on. a D:caftz 
a nd Graf (46 ) a nd Blanchard et al. (43) have r eported o n 
this instrument, whi c h uses a l aser -light scattering prin-
cj_ple. Sizj_ng and counting of particulates are made on the 
parenteral conten ts in their container a nd t h us the method 
i s con sidered to be nondestructive. Both s tudies (43,46) 
r eported the inherent advantages and disadvantages of th e 
Prototron and stated that its u se should be f urther inves-
tigated. As reported by Draftz a nd Graf (46), par ticles 
g r eater than o n e vm were recordable. 
In a recent report La nt z et al. (47) have described 
a The Nuc l eopor e Corpo r at ion, Pleasa nton, CA 
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the use of the HIAC Particle Countera for monitoring par-
ticulate matter in parenteral solutions. This instrument 
is a device using electronic stream scanning of particulates 
in the solution and operates on the principle of light 
blockage. It is capable of rapid and accurate counting of 
su.bvisual particles. The work of Lantz et al. described 
the advantages and disadvantages of this instrument. 
Studies employing a membrane filtration technique 
followed by scanning electron microscopy have recently been 
presented in the literature demonstrating the value of this 
method for the examination of.the topographical configuration 
of particulate matter (18, 23,24, 109). · Levinson e~ al. (18) 
used this method for "she comparison of infusion particu1 ates 
found in gla<os and plastic containers. Rebagay ~ a~. (23, 
24) used thi.s technique to observe residues in antibiotic 
preparations. Winding and Helma (109) have recently reported 
the use of scanning electron microscopy and X--ray analysis 
of particles exceeding 0.2 ~m. The X-ray analyzer coupled 
to the microscope could not chemically identify biological 
materials and other organic materials but could identify 
elements 9 through 93 in the periodic table. 
Viral Contamination of Parenterals 
Various types of contaminants have been found in paren-
teral flulds and many methods have been used in their 
~Ugh Accuracy Products, Clairmont, CA 
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detection . The articles published to date on large volume 
parenterals have reported contaminants with particle size 
above 0.2 ~m . The presence of particulates less than 0.2 ~m 
has not yet been described for parenteral fluids . Thus, 
the nature of these contaminants or their clinical signifi-
cance cannot be assessed. 
A suspected contaminant of large volume parenterals in 
this submicron size range might be the virus. Viruses are 
reported to range from approximately 18 nanometers (nm), as 
exemplified by the PicornR..~_iruses, to about. 300 nm in size, 
as observed i.n the ~_oxv:~_ru.scs. (98) . The significance of 
the virus has and is still being reco~nized in both clinical 
medicine a nd epide miology. 
If viral contaminant s exist in pare nt eral f luids, a 
grave at,ci imp8nding danger exists for the patie n t r e ceiving 
this "therapy." A patient undergoing parenteral therapy 
undoubte dly receives it to facilitat e correction of some 
pathological state . Such an ill person may be immunolog ically 
deficient at the t ime of· therapy. As Gross and Carter ( 5) 
have stated, recumbent positions and concomitant therapy 
especially with large dos es of corticosteroids are factors 
which influe nce the pathogenicity of contaminated infus ions . 
With the present medical trends in transplants and corres po nd--
ing use of immunosuppressants, viral contaminants infuse d 
directly into the blood stre am of these patients ma y b e 
clinically significant. In those patients who are immuno-
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logically compe t ent, a parenterally infused virus can cause 
disease (48). Furthermore, slow, inapparent and r ecurrent 
viruses can persist in the ir host without - the clinica l signs 
·of disease , yet cause chronic degenerative maladies clini-
cally expressed at future times (49). Thus, any huma n virus 
can be c U.nically signi f icant when administered p ar ente rally 
in an appropriate human hos t. Only s peculat i on is possibl e 
about the health significance. o f parenterally infused non-
human viruses . 
The hypothesis that viruses may ccntamina t e large 
volume parent e rals receives support from the Ame ri can Public 
Health Assoc i at i on's concern r egarding the potential health 
hazards of waterborne viruse s . This Association's Inte r-
national Conference on Viru ses in Water was .he ld in Mexico 
City in 1.974 (99,111). Several recomme ndations for environ-
mental health safety, r esearch, and de t ect i o n me thods 
resulted from this conference (100,111) . Articles have 
appeare d in the lite rature r egarding the presence and sig-
nificance of viruses in ·water supplies (101-106). At 
present, neithe r parenteral manufacture rs nor the Fe deral 
Food and Drug Administration's Parent eral Quality Control 
Laboratori es routine ly monitor parente~al contamination by 
viruses (11 2 ) . Personnel at a Fe de r a l Food and Drug Admin-
istration's Quality Control Laboratory have expresse d thei r 
be lief that viruses could contaminate parenterals espec i a lly 
where aseptic filling, final sterilization by filtr ation, or 
parenteral admixture are performe d (112). 
1.5 
Viral Contaminant De tection in Parenterals 
The initi~l problem in the development of a met hod for 
the de termination of virus contamination of parenterals is 
that of concentration or extraction of the virus from these 
solutions by an efficient means. 
Chromatographic and membrane separation methods (92), 
molecular sieving methods (93), electrophoretic methods (94), 
ultracentrifugal methods (86-89), and filtration methods (90, 
91,107,108) have been used successfully in virus concentra-
tion. Because of the quantity and the nature of the solu-
tions studie d, the filtration me thod is most amenable to 
efficient concentration. 
The specific filtration procedure which affords virus 
concentration is molecular filtratj .on. Molecular filtration 
has bee n d esc.ribed as a "technique for separating dissolved 
molecules on the basis of size by passing a solution through 
an infinitesimally fine filter. This molecular filter is 
a tough, thin, selectively permeable membrane whicp retains 
most macromolecules above a certain size, while allowing 
most smaller molecules, including solvent to pass into the 
filtrate" ( 108). Molecular filters are ava.i lable with dif -· 
ferent retention abilities which are characterized by their 
nominal molecular weight limit. Molecules with molecul a r 
weigh~s above this limit may be retained in a retentate 
volume, howe ver the size and shape of the molecul e also 
influe nce retention phenomenon. This nominal molecular 
weight limit serves as a guide to filter selection. 
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After filtration the retentate volume, usually less 
than three milliliters (ml), contains the concentrated virus. 
If it is necessary, the virus may be. further concentrated 
by ultracentrifugation (107) or by further molecular filtra-
tion to even smaller retentate volumes (108). 
Once virus concentration has been accomplished, electron 
microscopic examination of this concentrate using negative 
staining techniques allows visual detection of virus con-
taminants. Through initial electron microscopic examination, 
viruses can be classified into three general structural 
' ., 
configuraU.ons: rod shaped, spher·ical, or tadpole shaped ( 98). 
As shown by Horne and Wildy ( 82,84), virion synnnetry, espe-
cially caps1.d symmetry, is a useful criterion for virus 
classification. Negative staining methods for transmission 
electron microscopy have provided valuable information in 
the revelation and study of virus particles (74-85,96,97). 
The "drop method" as deseribed by llaschemeyer and Myers (74) 
is the most amenable technique for the embedding of the 
specimen sample in the negative stain where viral concentra-
tions may be low. 
OBJEC'I'IVES 
The primary objective of this project will be to de-
velop an accepted research method for determining the presence 
of viruses in small volume as well as bulk parenterals. 
'!'he following methods and procedures used to attain 
the objective of this endeavor will include: 
l. defined volumes of the parenterals will be 
inoculated with specific quantities of Tobacco 
Mosaic Virus var. vulgaris Ul, used as the 
rnodelviral contaminan:r;-to test the efficacy 
and efficiency of the detection method; 
2. the contents of the selected parenterals will 
be concentrated to an appropriate retentate 
volume using molecular filtration through a 
filter of suitable nominal molecular ·wej_ght 
limit, capable of retaining viruses; 
3. this retentate volume will be examined for 
viral content using transmission electron 
microscopy with negative staining techniques; 
4. defined volumes of Sodium Chloride Injection 
U.S.P. and 5 percent Dextrose Injection U.S.P. 




In this research endeavor, a method was developed to 
detect viral conta_minants in parenteral solutions. This 
method was analyzed for its efficacy and efficiency. The 
term "efficacy," as used in this project designated the 
capability of viral detection by the method. 'l'he term "effi-
ciency" denoted the viral contamination level at which viruses 
were detectable. 
The Model Virus 
The virus chosen for use as the inoculant· for contami-
nating the parenteral solutions was Tobacc~?. Mosai~ V~rus (TMV). 
This RNA virus is a plant pathogen possessing well defined 
rod shaped morphology and helical symmetry with respect to its 
nucleic acid core. The virus is approximately 300 nm in 
length and 17 nm in diameter (82). Most viruses studied to 
date have sizes within this range (98). Because TMV has 
characteristic geometry and virion dimensions representative 
of the major viral groups, this virus was used a_s the model 
virus for this study. 
Tobacco Mosaic Virus is a chemically stable virus and 
shows an inactivation rate independent of pH in the range of 
18 
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4.0 to 8.5 (113). A pure culture of the virus is stable in 
dilution in Sterile Water for Injection U.S.P. for about a 
year (114). These factors were advantageous for viral sta-
bility considerations in the parenteral solutions examined. 
Fraenkel-Conrat (115) described a relationship between 
weight, viral particles, and plant lesions for TMV. One 
plant lesion is produced in Nicotiana tobaccum var. Xanthi 
for approximately every 0.1 n~.nogram (ng) or 106 virus par-
ticles. Thus, one infectious unit (I.U.) corresponds to 
approximately 106 virus particles for TMV (116). 
In this experimentation, viral dilutions of pure stock 
cultures of :robacco ~o~~:i:c£ .Yirus var. vul~qris Ul strai.n, a 
were prepared using molecularly filteredb Sterile Water for 
Injection U.S.P.c as a vehicle. The required vol.umes were 
micropipettedd ihto sterile one ml glass s~oppered volumetric 
flasks.e The micropipette tips had been ethylene oxidef 
kObtained from T. Shalla, Ph.D., Dept. of Pl~nt Pathology, 
University of California, Davis, CA. 
bl42 mm Hi Flux U-F Cell equ:ipped with a Pellicon PTGC 
membrane, 10,000 nominal molecular weight retention limit, 
available from Millipore Corporation, Bedford, MA. 
cAbbott Laboratories, North Chicago, IL. 
dFinpipette, Code 11, available from Vangard Interna-
tional, Neptune, NJ. 
e Class A, Pyrex Brand, available from Dow Corning, 
Midland, MI. 
fPenngas, available from Pennsylvania Engineering Co., 
Philadelphia, PA. 
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steri.ltzeda prior to their use. All dilutions were prepared 
in a laminar a~r-flow area using a Class 100 high-efficiency 
particulate absolute filter.b 
Preparat ion and Monitoring of Molecularly Filtered Sterile 
Fat~I- for Inj ection 
Throughout this investigation molecularly filtered 
ste ril e water for injection (W!'SWFI) was used. This water 
was Sterile Water for Injection U. S.P. (SWFI) whic h had been 
subjected to molecular filtration to remove any particulate, 
bacterial , fungal, or viral contamination. 
Liter (L) volumes of SWFI were filtered throug h a 
Pellicon molectilar filter having a nominal molecular weight 
r etent ion limi t of 10,000. Thi s filter was cont ained in a 
142 mm Hi Flux U-F Cell. The solution was loaded into the 
(' 
cell by use of a .standard i n travenous administration set. · 
A l r- t 20 . d d . . f t d b d d ~ o pslg. r1v1ng ·orce was genera e y ry gra e 
nitrog~ne passed through a 25 mm, 0.2 ~m inline Fluoropore 
aAMSCO Cryotherm and Aerator, available from Amsco 
Industrial Co., Erie, PA. 
bGEN II , available from Plas-Labs , Lansing, MI . 
c Ve noset-60, available from Abbott La boratories, North 
Chicago, IL. 
d Pounds per square inch gau ge . 
eAvailable from Union Carbide Corp., Linde Division, 
New York, NY. 
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filter.a A Hi Flux U-F Cell agitator setting of two was 
used during the filtration. The filtrate was collected in 
stoppered, sterilized flasksb and stored in a laminar flow 
hood. 
All filtration equipment including accessories was 
cleaned, then ethylene oxide sterilized prior to use. Through-
out the project any equipment not subjected to this type of 
sterilization was either dry heat sterilizedc at 160 to 170° C 
d for at least three hours or autoclaved at 15 psig. and 
121° C for the correct penetration time for the load. Chemi-
cal indicatorse,f were used to monitor the sterilization 
procedures. 
The entire filtration procedure was performed in a 
laminar air-flow work area containing a Class 100 high-
efficiency particulate absolute filter. 
Whenever MFSWFI was prepared, contamination control 
aMillipore Corporation, Bedford, MA. 
b Fleakers, available from Dow Corning, Midland, MI. 
c Thelco Dry Heat Oven, available from Precision Scien-
tific Group, GCA Corp., Chicago, IL. 
dModel No. 999 - C, available from Wilmot Castle Co., 
Rochester, NY. 
eEthylene Oxide Indicator, available from Aseptic 
Indicator Co., North Hollywood, CA. 
f3M Autoclave Tape, available from Minnesota Mining 




detection procedures were used. The stored filtrate was 
subjected to sterility testing for bacterial and fungal con-
tamination. The following procedures were used: 
At least 10 ml of MFSWFI were aseptically transferred 
to not less than 80 ml of sterile Fluid Thioglycollate 
Mediaa (FTG) and to not less than 80 ml of sterile 
Sabouraud Dextrose Brothb (SDB). At the same time 
blank controls, as well as contaminated controls were 
prepared. The blank controls detected contaminated 
media or septic procedures. The contaminated controls 
were used to test the media's ability to support bac-
terial or fungal growth. A contaminated bacterial 
control was prepared by inoculating nat less than 
50 ml of FTG with Ba~_:i,l..!_~s subtilj~· c A .contaminated 
fungal control was prepared using Can_dis!~ _i!:._l_!:li~'':E!..."::d 
inoculated into not less than 10 ml of SDB. The 
bacterial contamination tests were incubatede at 
30 to 32° C, whereas the fungal contamination tests 
were incubatedf at 22 to 25° C. The tests were checked 
aDifco Laboratories, Detroit, MI. 
bibid. 
c Bakte Bennet Labs., Berkeley, CA. 
dibid. 
eThelco Incubator, available from Precision Scientific 
Group, GCA Corp., Chicago, IL. 
flbid. 
23 
for growth daily for not less than 14 days. 
The results of_all tests performed showed no bacterial or 
fungal contamination of the MFSWFI or the blank contro ls. 
Growth occurred in all contamination controls. 
To determine the presence of inc idental viral contami-
nat ion of the MFSWFI by TMV or any o the r virus, the fol l.owi ng 
procedure was used: 
The residual volume of SWFI r emaining in the lii Flux 
U-F Cell was remove d by nitrogen pressure via the 
cannula attached to the cell. Sterile s urgical tub inga 
attached to the cannul a enabled the collect i on of the 
sample in a sterile 20 by 150 mm · Pyrex test tube.b This 
r es idual volume was r eferred t o as the retent ate volume. 
Two to four: drops of the f Jl tra te, MFSWF I. , were a l s o 
collected in another sterile test tube. The inline 
Fluo r opore filte r used t o filter the nitrogen was asep-· 
tically remove d in the l amin a r a ir- flow hood. It was 
transferre d to another sterile tes t tube cont a ining 
0 .5 ml of MFSWFI. The r etentate volume, f iltrate, and 
inline filt e r collect volume were the n prepared into 
negativ EC stained specimens for tra nsmiss i on electron 
microscopy by the fo llowing procedure: 
Two microl ite r s (~1) of each solution were deposited 
aTygon tubing S 50-HL, available f rom Norton Plastics 
and Synthetics Divis i o n, Akron, OH. 
bAvailable from Dow Corning, Midland, MI. 
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on 400 mesh copper grids . a In a laminar flow hood 
the grids had been subst~ated with Formvarb and 
stabilized with a layer of vacuum evaporatedc car-
bon. The solutions were deposited on the grids 
by the use of sterile micropipett es.d Two ~1 of a 
0.5% wfv solution of uranyl acetate (UA) in MFSWFI 
were then deposited to the grid. This embedded 
the sample specimen in the UA negative stain. This 
procedure has been described by Hasch emeyer and 
Myers (74) as the "drop method." Prior to the use 
of the UA solution, it had been filtered through a 
25 mm PTGC Pellicon fil tere . po.ssessing a nominal 
molecular weight retention lim:i t of 10 ) 000 . rrbe 
grid pre paration was allowed to dry comp le tely in 
the le:tminar air-flow envlronment . It was t hen 
f g examine d jn the transmission e l e c t ron microscope ' 
at 50 or 60 KVh and a magnlfication of at leas t 18,000. 
aAvailable from Ted Pella Co., Tus tin, CA. 
b0.2 pm Fluoropore filt e r e d 0.25% wfv Formvar in Ethylene 
Dichloride. 
cVari a n Vacuum Evaporator, VE 10, available from Varian/ 
Vacuum Division, Palo Alto, CA. 
dAvailable from Drummond Scientific Co., Broomall, PA . 
eMillipore Corporation, Be dford, MA . 
fRCA TEM EMU3-DX, available from Radio Corp . o f America, 
Camden, NJ. 
gSieme ns Elmiskop TEM IA, available from Si eme ns o f 
America, Inc., New York, NY . 
hKilovolts. 
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Throughout the project TMV was not detect e d in any of these 
control specime_ns for MFSWFI. 
A procedural diagram of the preparation and monitoring 
of MFSWFI is presented in Figure 1. 
Parenteral Solutions 
In this study defined volumes of Sodium Chloride Injec-
tion U.S.P. and 5 percent Dextrose Injection U.S.P. were the 
parenteral solutions examined. Identical lots of the speci-
fied volumes of each solution were randomly chosen. These 
were then used throughout either the preliminary tests 
involving small volume parenterals or the tests with large 
volume infusions. 
These two parenteral so lutions were chosen because 
they or their varying combinati.ons comprise the most corrunon l y 
administered intravenou s infusions. 
Preliminary Tests with Small Volumes of Parenteral Solu!tons 
The Test Method 
A 10 ml aliquot volume was aseptically r emoved from a 
50 ml volume of either Sodium Chloride Inj ection U.S.P.a 
or 5 percent Dextrose Injection U.S.P.a This volume was 
transferred to a ster ile 16 mm by 125 rnm test tubeb for each 
aMcGaw Laboratories, Irvine, CA. 
bPyrex brand, available from Dow Corning, Midland, MI. 
------------~~~--------------------------~-------------------------------.----1-------------------
Clean i ng and Load and Collect l iltrate 
Steri l ization of the Filter (MFSWFI) 
Hi Flux U-F Cell and SWFI 
















J I ~ 
/! '\ 
/ l ~ 
Sterility 
Testing for 









TMV or Other 
Contaminants 

















Figure 1. Procedural Diagram of the Preparation and Monitoring of Molecularly 





analysis. This solution was inoculated with TMV by the use 
of a micropipette with a sterile tip. The virus was obtained 
from the serial dilutions of TMV already described. 
After inoculation, the solution was gently agitated 
and then filtered using a Pellicon PT series molecular fil-
t "t a er un1 ·. The filter on this unit had a surface area of 
ll cm2 b and a nominal molecular weight retention limit of 
10,000. The solution was filtered by the use of a vacuum 
c pump attached to a collection reservoir. The retentate 
volume remaining in the test tube after filtration was 
approximately 0.2 ml. The test tube and filter were then 
washed with a five ml portion of MFSWti, again conceatrated, 
then rewashed wi t.h another five ml . volume of ~lFSWFI. This 
volume was again reconcentrated to 0.2 ml. After each fil-
tration procedure, the filter was tested to ensure filter 
integrity as described by the manufacturer (120). 
Two ~l volumes of this retentate volume were deposited 
using a sterile micropipette on Formvarjcarbon substrated 
400 mesh copper grids. A two lll volume of 0.5% wfv uranyl 
acetate solution in MFSWFI was then placed on the specimen 
grid. For each test specimen four grid preparations were 
aimmersible Molecular Separator, available from MillJ.-
pore Corporation, Bedford, MA. 
b Square centimeters. 
cAvailable from Millipore Corporation, Bedford, MA. 
28 
made. Two of the samples were allowed to dry completely on 
the grids and two were blotted with sterile filter po.per 
after five minutes from the time of application of the stain. 
All procedures described above were conducted using aseptic 
techniques in a laminar air-flow environment. 
To single blind the experiments, the specimens were 
exami.ned for the presence or absence of TMV by an electron 
microscopy technician. Prior to this study, the technicians 
were instructed in the technique of negative staining and 
transmission electron microscopic observation of TMV. 
Cleaning, ~anitizing, and Sterilizo.tion of the 
Molecular Filters 
At the completion of each test using rr.olecular fil h·a--
tion, the filter was cleaned with a one % wjv sodium hypo-
chlorite solution for at least three hours. This solution 
was discarded after passing through the filter. At least 
50 ml of MFSWFI were used to rinse the filter and the filter 
unit's inner matrix. The filter was then flushed with and 
placed in a two % wjv formaldehyde solution for not less 
than 14 hours. This formaldehyde solution was passed through 
the filter and discarded. At least 80 ml of MFSWFI were 
filtered through the membrane before its use in the next 
test. After every fifth test, a new molecular filter was 
j selected and ethylene oxide sterilized prior to use. 
i 
Figure 2 diagramatically describes the test method as 
well as the cleaning, sanitizing, and sterilization procedures 
I. 
Sterilization Load Test Tube Flush ~ Retain 7Examine 
of ll cm2 /) with Parenteral, ) with 2 - 5 ml Retenta te Using 
Molecular Inoculate with TMV, Volumes of Volume N.S. 
Filter ~ and Filter MFSWFI and 
Corcentrating to 
Retentate Volume 
Concentrating to EM 
Retentate Volume 
of 0.2 ml of 0.2 ml for 
Each Flush 
Clean Fi~h ~heck 




R1nse and Flush 
Filter with Not Less 
Than 50 ml of MFSWFI 
~ 
Sanitize Filter 
with 2 % wjv Formalde-
hyde Solution 
J 
Rinse and Flush 
Filte~ with Not Less 
than 80 ml of MFSWFI 
Figure 2. Procedural Diagram of the Pr~liminary Tesc Method with Small Volumes 




used with small volumes of parenteral solutions. 
Detection of TMV at Varying Viral Contamination Levels 
Initially, it was necessary to identify approximate 
viral contamination levels which the test method could de-
tect. The test method as described above was used for all 
of these determinations. The amount of the viral inoculum 
and tho parenteral used in each test are shown in Table I. 
The tests were first conducted using Sodium Chloride 
Injection U.S. P. The tests were then repeated using 5 per-
cent Dextrose Injection U.S.P. at the lower contamination 
levels. These tests were concluded when a level of contami--
nation in Sodium Chloride Injection U.S.P. was reached at 
which TMV could not be detected. The results are reported 
in Table I. 
Based on the results of these tests, the 100 I.U. and 
l I.U. TMV contamination levels were chosen to evaluate the 
efficacy and efficiency of the test method. Suitable con-
trols were established. Replications of each control and 
test treatment were performed to provide statistical validity. 
Efficacy Determination at a Contamination Level of 
100 I. U. of TMV per MilliUter of Sol11tion 
To determine the efficacy of the test method with small 
volumes of parenteral solutions at a contamination level of 
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less than 1 
aTMV observed. 








Ten ml of Sodium Chloride Injection U.S.P. were 
aseptica~ly removed from a 50 ml volume of this solution 
and transferred to a sterile 16 mm by 125 mm test tube. 
This sol uti on was inocula ted with 100 I. U. of TMV as 
performed in the initial tests. The solution was 
gently agitated to disperse the virus. Two )11 of this 
mixture were then deposited on a Formvarjcarbon sub-
strated 400 n•esh copper grid and negatively stained 
by the prior method. Electron microscopic examination 
followed. This procedure was repeated for a total of 
three replications with Sodium Chloride Injection U.S.P. 
and followed by three replications with 5 percent 
Dextrose Injection U.S.P. Thus, these contaminated 
solutions were examined for detectability of TMV without 
use of the test methodology. The results are found in 
Table II. 
After these control tests, the same inoculation 
procedure with 100 I.U. of TMV was performed on the 
same volumes of the parenterals. These were then sub-
jected to the filtration methodology described above 
in the initial tests. Three replications were conducted 
with Sodium Chloride Injection U.S.P. and then repeated 
with 5 percent Dextrose Injection U.S.P. Single blind 
electron microscopic examination was performed after 
the use of the test methodology. These results are 
also presented in Table II. 
TABLE II 
PRELIMINARY TEST RESULTS 
Determination of the Efficacy of the Test Method 
with ,?EJall Volumes of Parenteral Solutions 
at a Contamination Level of 100 Infectious 
Units of Tobacco Mosaic Virus per 
-~-Mill-iliter of Solution-
TMV Not TMV 
Observed Observed 
Examined Without 
Use of the Test 6 0 
Methodology 
Examined After 
Use of the Test 0 6 
Methodology 
Total 6 6 







The data presente d in Table II and all subsequent 
tables throu ghout thi s resear c h we re analyzed by the 
Fishe r e xact probability t est (117). 
Efficacy Determination at a Contamination Leve l of· 1 I . U. 
~-~ TMV p e r Millilite r of Solution 
Once efficacy de termination o f the t es t method had been 
completed at a contamination l eve l of 100 I . U. of · TMV p e r ml 
of pare nte ral, the entire proce dure describe d abo ve was re-
pea ted . Thi s proce dure was rep eated with a TMV con tamination 
level o f 1 I.U . per ml of solution. Us ing the same vo lumes 
and the same parenteral solutions, si~ replications were 
p e rformed at this contamination l eve l without the use of the 
test me thodology . These were fo llowed b y six r~plications 
fi s ing the t est procedure . Sin g l e blind examin ation was con-
ducted on a ll specime ns. The r esults are s hown in Table I II 
for contaminat ion l e ve l s of 1 I . U. per ml of solution . 
Efficiency Determination at a Con tamination Level of 
100 I.U . of TMV p~r Milliliter of Solution 
The eff i cien cy of the t est method with small volumes 
of the pare nte r a l s at a contamination level of 100 I . U. of 
TMV per ml of solution was dete rmine d. Three r epl icates of 
10 ml volumes of Sodium Chloride Injection U. S . P . a n d three 
r ep l i cat es of 10 ml volume s o f 5 p e r cent Dextrose Inj ection 





PRELBliNARY TEST RESULTS 
Detcrmina t ion of the Effi.Cf!S.Y.: of the Test Method 
with Small Volumes of Parenteral Solutions at 
a Contarnfnation Level of 1 Infectious Unit 
of Tobacco Mosaic Virus per Miliiliter 
----of-Solution 
Examined Without 
Use of the Test 
Methodology 
Examined After 




















In the first group of tests, the control group, the 
parenterals were not contaminated with TMV. The second group 
of tests, the treatment group, was contaminated with 100 I.U. 
of TMV per ml for each test solution. Thus, one group was 
not contaminated and the other group was contaminated with 
the virus. 
Each parenteral test specimen in a group was subjected 
to the filtration test method described in the efficacy deter-
minations. The cleaning, sanitizing, sterilizing, sampling, 
staining, and examining procedures accompanying the filtration 
were used and remained unchanged. The results of electron 
microscopic examination of the specimens for the presence or 
absence of 'l'MV are found jn Table IV. A representative elec-
tron micrograph is provided in Figure 3. 
Ef_fieiency De_terminaUon at a Contamination .. ]k_Y-<':.!_of 
1 I.U. of TMV per Milliliter of Solution 
The efficiency of the test method was next determined 
using a contamination level of 1 I. U. of TMV per ml of the 
parenteral solution. The same parenterals, volumes, and 
replications were used here. The uncontaminated control 
and the contaminated treatment groups' observations are sum-
marized in Table V. Figure 4 illustrates the typical find-




PRELIMINARY TEST RESULTS 
Determination of the Efficiency of the Test Method 
with Small Volumes of Parenteral Solutions at 
a Contamination Level of 100 Infectious Units 



























Figu re 3. El ect ron Mi crograph o f Tobacco Mosaic Vi rus 
De t ect e d at a Con taminat i o n Leve l o f ---
100 Infec t ious Un its per Milliliter o f 
Sma ll Volume Parenter a l Solut i o n 
(Magn ificat ion 98 ,000x ) 
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TABLE V 
PRELIMINARY TEST RESULTS 
Determinat ion of the EtficiencY._ of the Test Method 
with Sumll Volumes of Parenteral Solutions at 
a C;on-tarr1ina.tion Level of 1 Infectious Unit 
of Tobacco Mosaic Virus per Milliliter 
--of- So 1 ut ion 
Uncont aminat ed 
Parenteral Examined 
After Use of the 
Test Me thodology 
Contaminated 
Parent eral Examined 
After Us e of the 

















Figure 4. El ec tron Micrograph of Tobacco Mosaic Virus 
De tecte d at a ContaminatianLe vel - of--1--In fec-
tious Unit per Milliliter of Small Volume 
Parente r a l Solution. (Maguif ieation 98,000x) 
40 
41 
Tes ts with La rge Volumes of Pare nt e ral Solutions 
The Tes t Method 
The test method for the de tection of viral contaminatio n 
of small volume parenterals us ed a molecular f iltrat ion mem-
. 2 
brane with an a r e a of ll em . For bulk p a rent erals, a l arger 
filtration me mbrane wa s neede d to r e duce fil t r ation time. 
The Hi Flux U-F Ce ll, e quippe d with a 1'12 mm molecul a r f il·-
ter with a no minal molecul a r we i ght r e t entio n limi t o f 10,000 , 
was chosen to provide large volume filtra t i on . The 142 mm 
membrane provided 158 . 37 cm
2 
of filtrat ion ar e a. Thi s c e ll, 
filter, and the acc ess o r ies acco mpany ing their use , h a v e b een 
described in ~he p r eparat i on o f MFSWFI . 
A o ne liter vo lume of e ithe r So dium Chl ori dg I nj e c t ion 
US a I . t' p c· r -a t ' . .... P. or :'>pe r cent Dextrose DJ ec 1-011 u . •. . r ' . wa.s asep 1.-
cally transferre d t o the cell by a stand~rd i n travenous ad-
.. t t . .t b m1 n1s r a 1on se . The c e ll i nl e t port a l was sea l e d a nd a 
15 to 20 p s i g. drivi n g fo r ce was applie d by dry g r a de nitro-
c . 
gen' passed through a 2 5 mm, 0 . 2 ~m inline Fluo r opor e f il-
d 
t er . Once t he cell v e n t v a lve was c losed, f iltration began . 
Dur ing fi l t r a tio n a cell agita tor set ti ng of t wo was u sed . 
a Abbott La b orat ories , North Chicago , I L . 
b Ve noset -60, avai l abl e fro m Abbo tt La bo r a t ories , North 
Chicago , IL . 
c Ava i lable fro m Unio n Carbide Co r p . , Li nde Di v i s i on , 
New Yo r k, NY . 
dMill ipore Corporat i o n, Be dfo rd, MA . 
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The agitator prevented concentration polarization at the 
membrane surface, which would reduce the flow rate and alter 
the retention characteristics (108). The solution was con-
centrated to a volume less than three ml. 
After this initial filtration procedure, the c e ll was 
aseptically filled with approximately 250 ml of MFSWFI . This 
volume was then filtered and concentrated to less than three ml. 
Again 250 ml of MFSWFI were aseptically added to the cell. 
This final rinse was filtered and concentrated to less than 
thre~ 1nl. Just prior to the final concentration, about 0 . 2 ml 
of the filtrate was collected in a sterile test tube and 
retained for analysis. 
The retentate ~olume in the cell was aseptically removed 
through the cell cannula by nitrogen pressure .· Tl1e retentate 
volume was forced through the cell c&nnula, sterile surgical 
a . 
tubing, and another cannula into a sterile 20 by 150 mm 
Pyrex t est tube. b 
Once this retentate volume was collected, the volume was 
further concentrated to approximately 0.2 ml. 2 An ll em 
Pellicon PT series molecular filter unit with a nominal molec-
ular weight retention limit of 10 ,000 was u sed for this con-
centration procedure. 
aTygon t~bing S 50-HL, available from Norton Plastics 
and Synthetics Division, Akron, OH. 
bAvailable from Dow Corning, Midland, MI . 
43 
This r etentat e volume and the collected filtrat e were 
subjected to the same negative staining procedure and single 
blind electron microscopic examination as described in the 
preliminary tests. The same volumes of the sample and stain 
as well as the same number of grid preparat.ions per specimen 
were used. 
All of the above procedures for the test me thod were 
conducted in a lamina r air-flow hood. 
Cleanin~1 S a nitizing, and Sterilization of the Cell and 
th e Molecular Filter 
2 After each test the 11 em molecular filter unit was 
cleaned with sodium hypochlorit e solution and sanitized with 
formald ehyde solution. Tlle procedure has been descrtbed in 
the preliminary tests. Following ever y fourth test, a new 
filt er unit wa$ selected. Prior t o its use the new unit was 
ethylene oxide sterilized. 
The Hi Flux U-F Cell and the 142 mm molecular fj.l ter 
we r e cleaned and sanitized in situ by the foll owing proce-
dure : 
1. A 500 ml volume of one % wfv sodium hypochlorite was 
placed in the cell by use of a standard intravenous admini-
stration set. This cleaning solution was agitated in the 
cell and a small volume was allowed to pass through t h e 
filter. The remainder of the solution was retained in the 
cell for at least three hours. After this interval , the 
solution was filtered and discarded. 
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2. The cell was then rinsed with two, 250 ml volumes 
of MFSWFI . Eac h volume was agitat e d throughout t h e cell, 
then flushed throu gh the filt e r . 
3. Five- hundre d ml of two % wjv formald e hyde solution 
were placed in the cell. This was followed by co nt r olled 
agitation to e nsur e a uniform covering of the cell s u rfaces . 
A s ma ll volume of this solution was filtered through the mem-
bra n e . The n the solu t i o n was r etaine d in the cell for not 
l ess than 14 ho urs . At the e nd of this sanitizing procedure, 
the cell was flus hed a nd the so lutio n was d isca rded . 
4. A 250 ml volume o f MFSWFI was placed in the cell . 
Th e cell was thorou ghly rinsed with t h e MFSWFI. The MFSWFI 
was then fi ltered through the membrane. This r insing pro-
cedure was performed a t o t a l of four t imes to .e f fective l y 
r emove traces of forma ldehy de. Th e MFSWFI userl f or the fourth 
rinse was coll ~cted a nd analyzed for its forma ldehyde con-
t e nt . . Th e retentate volume was analyzed for r esidua l TMV by 
the t est method described previously . TMV could not be 
detect e d in this rinse retentate volume throughout the tests. 
The fo rma ldehyde cont e nt i n the rinse was a n a l yzed by a pro-
cedure simi l a r to the method described in t h e U. S . P . (lJ.B) 
and the method of Bricke r an d J ohnso n (119). Th e followin g 
procedure was us e d: 
Five mg of chromotropic aci d were dissolve d in t e n ml 
of a mi xture of nine ml of Sulfuric Acid U.S. P . a nd 




added to 0.2 ml of the formaldehyde rinse. The mixture 
was then heated for 10 minutes at 60°C on a water bath. 
A very faint violet color resulted. The amount of 
formaldehyde was determined spectrophotometricallya 
at a wavelength to 570 nm by comparison with a reagent 
blank. A series of formaldehyde reference standards 
were prepared and analyzed. A Beer's Law plot was con-
structed. The average amount of formaldehyde detected 
in the fourth rinse was less than 3.5 micrograms (~g) 
per ml. 
After the completion of every fourth test using the Hi 
Flux U-F Cell and its molecular filter, the cell was disas-
sembled, eleaned with mild detergent, and thoroughly rL1sed 
with copious volwnes of distilled water. The cell and its 
components were then dried in a laminar air-· flow hood. After 
drying, a new 142 mm molecular filter and a new inline Fluoro-
pore filter were installed. The cell and all accessories 
were then ethylene oxide sterilized. 
At this disassembly time, the Fluoropore inline filter 
was aseptically removed in the laminar air--flow hood. The 
filter was placed in a sterile test tube containing 0.5 ml 
of MFSWFI. The tube and its contents were agitated. Nega-
tively stained specimens were then prepared for electron 
•Perkin-Elmer Model 202 Spectrophotometer, available 
from Perkin-Elmer, Norwalk, CT. 
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microscopic examination. This procedure has been described 
in the preparation and monitoring techniques for MFSWFI. 
Throughout the experimentation TMV was not observed in these 
Fluoropore filter washings. This procedure was used to 
detect incidental contamination from the nitrogen sourc~. 
A procedural diagram of the test method including the 
cleaning, sanitizing, and sterilization methods is shown in 
Figure 5 for large volume parenterals. 
Efficacy Determination at a Contamination Level of 
lOO __ !..:_Q_,__of TMV per Milliliter of Solution 
The efficacy determination tests performed with large 
volume parenterals were similar to those executed in the pre-
liminary tests with small volume solutions. The control tests, 
which were examined without use of the test methodology, were 
conducted exactly as described in the preliminary tests using 
100 I.U. of TMV in 10 ml aliquot volumes of the parenterals. 
However, the procedure was repeated for a total of four rep-· 
lications with Sodium Chloride Injection U.S.P. and followed 
by four replications with 5 percent Dextrose Injection U.S.P. 
The results of the control tests inoculated with virus but 
examined without use of the test methodology are described in 
Table VI. 
Following these control tests, 1000 ml volumes of the 
parenterals were placed in the Hi Flux U-F Cell and inocu-
lated with 100 I.U. of TMV per ml. Inoculation was performed 
by use of a micropipette with a sterile tip. The contaminated 
_ ............. , •.• , ...... 1 •..••• ,. 
Sterilization Load Cell Flush with Remove Retain ) Examine 
of Hi Flux ~with Parenteral, ) 2 - 250 ml Volumes Retentate Retentate Using 
U-F Cell, Inoculate with of MFSHFI Concen- Volume Volume N.S. 
Molecular /f THV, and Filter trating to Retentate from Cel/ and 
Concentrating Volume of Less Thavand Retain EM 
Volume of Less ~ \V 
to Retentaye 3 ml for Each Flush I 
Than 3 ml Clean Hi Flux U-F Cell Concentrate to Sterilization 
and Molecular Filter Retentate Volume of 11 cm2 
Collect 0. 2 ml in situ with 500 ml of 0. 2 ml with ~ Molecular 
of Filtrate of 1 % w/v Sodium 11 cm2 Molecular ~ Filter 
Jr Hypochlo~te Solution Filt~ 
Integrity Test Rinse and Flush Cell Clean Filter with 
Filter for THV and Filter with 2 - 1 % w/v Sodium 
Breakthrough 250 ml Volumes of Hypochlorite 
Using N.S. and MFSHFI j Solution 
D ~ ~ 
Sanitize Cell and Rinse and Flush Filter 
Filtec with 500 ml of with Not Less Than 
2 % w/v Formaldehyde 50 ml of MFSHFI 
Solution~ ~ 
Rinse and Flush 
Cell and Filter with 




Analyze Fou R entate VoJ.ume from 
MFSHFI Rinse for Foucth MFS'IFI Rinse 
Formaldehyde 
Traces 
for TffV and Otl1er Con-
taminants Using N.S. 
and EM 
Sanitize Filter with 
2 % w/v Formaldehyde 
Solution 
-t 
Rinse and Flush Filter 
with Not Less Than 
80 ml of HFSWFJ. 
_j 
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solution was processed by the test method . Four replications 
with Sodium Chloride Inj ect ion U.S.P. and four r eplications 
with 5 pe rcent Dextrose Inj ect ion U.S.P. were conducted . 
These res ults are summarized in Table VI. The 0.2 ml volume 
of filtrate coll ected at the end of each procedure did riot 
demonstrate any TMV breakthrough from the molecular fi l ter. 
Effj_ ~3CY _Dete rmination a t a Con t amtna t ton Level of 
1 I .U . of TMV_per Milliliter of Solution 
Afte r efficacy de termination of the test method had been 
completed a t a contamination level of 100 I. U. of 'l'MV per ml of 
bulk parenteral, the entir e procedure e numer ated above was again 
r epeated. For .these tests a TMV contamination level of 1 I. U. 
per ml of solution was used. The r esults of the controls, 
examined without use of the tes t met hodo l ogy, ·a nd th e test 
trea trnent gr oup, examin e d after use of th<~ t est method, a r e 
presented i n Tabl e VII. Again, the 0. 2 ml volumes of filtrate 
collected at the e nd of each procedure s howed no TMV breakthrough . 
Efficiency Determination at a Contamination Leve l of 
100 I.U. of TMV per Milliliter of Solutio~ 
The efficiency o f the test methodology with large volumes 
.of the parenteral soluticins was determined . The co ntaminatio n 
l evel of 100 I.U. of TMV per ml of bulk infusion was first 
examined . Lite r volumes of Sodium Chloride Injection U. S . P . 
and 5 percent Dextrose Injection U.S.P. wer e used in t he 
tests. Four replications of the test method fo r each of t he 
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The control tes t group of pare nterals was not contami-
nat e d with TMV: The test treatme nt group was contaminat e d 
with 100 I . U. of TMV per ml in each bulk pare nteral. Th e 
inoculation procedure was the same as that describe d fn the 
efficacy tes t s . Each infusion, whe ther contaminated or un-
contaminated, was subjected to the t est metho d de scribed 
prevj.ous ly. The res ults are r eporte d in Table VI II and 
illustrate d by a representative electron micrograph in Fig-
ure 6. No TMV breakthrough was found in the filtrate volumes 
collec t e d. 
Effici e ncy ~etermin ation a t a Contaminatio n Level o f 
1--l.:.!:!...:__s>f TMV pe r Millilit er of Solution 
The efficiency de t ermi nat i o n method presente d above was 
r e peated at a contamination l evel of 1 I.U . of TMV p e r ml 
of the parenteral. The same pare nterals, volumes, and replf-
cations we r e used for these tests . The un contaminated a nd 
contaminate d gr o ups ' r esult s are r ecorde d in Table I X. F'ig·-
ure 7 d emons trates the typical finding of e l ectro n micro-
scopic exami natfon . TMV breakthrou gh was not observed fn 
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Figure 6. Electron Micrograph of Tobacco Mosaic Virus 
De tected at a Contamination Level of lOb----
Infectious Units per Milliliter of Large 
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Volume Parenteral Solution (Mag11i fication 98,000x) 
TABLE IX 
TEST RESULTS 
Dete rmination of the Effic iency of the Test Me thod 
with La rge Volumes of Parente r a l Sol uU.ons at 
a Contamination Level of l Infect~o~s Unit 
of Tobacco Mosaic Vi~us pe r Milliliter 
----- of Solution 
Uncontamina t ed -
Parenteral Examin e d -
Aft e r Use of the 
Test 111e tho dology 
Contaminate d 
Parenteral Examine d 
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Micrograph of Tobacco Mosaic Virus 
at a Contamin a tion ·Levelof- 1.- Infectiou s 
Milliliter of Large Volume Parenteral 
(Magnification 71,000x ) 
DISCUSSION 
In this study both efficacy and efficiency were desired 
for the proposed test method of detecting viral contamination 
in parenteral solutions. The 100 I.U. a nd l I.U. TMV contami-
nation l evels identified in the preliminary tests enabl ed 
effective evaluation of the method. Using the preliminary 
test method, TMV was not detected at a viral contamination 
level less than 1 I.U. per ml of small volume parenteral 
solution. This was s hown in the r esult s- prese nted in Table I. 
For the prelimtnary tests with small volume parenteral 
solutions and the s ubsequent tests with l arge volume paren-
teral solutions, the controls used in the efficacy determi -
n a tions of t he ~est n~thod were contaminated with ei the r 
100 I.U. or 1 I.U. of TMV per ml of parenteral solution. 
These controls were examined for the presence of TMV without 
the use of the test method. As reported in Tabl es II, III, 
VI, and VII, TMV could not b e de tected. Wh e n specimens using 
Sodium Chloride Injection U.S . P . were examined in the electron 
microscope , a dense granular precipitate was observed. This 
precipitate hindered viral detection. Upon e xamination of 
spec ime ns using 5 percent Dextrose Inj ection U.S.P., s imil ar 
result s were obtaine d. The entire grid sur face of the 
sample was electron de nse . This opacity of the sample proba bly 
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resulted from caramelization of the dextrose in the electron 
beam. When the test method was used for the efficacy test 
treatment groups, viral detection was possible. The rinsing 
procedures and subsequent reconcentrations used in the test 
method reduced the concentration of the chemicals interfering 
with electron microscopic examination. 
When using small volume parenteral solutions, the pre-
liminary efficacy test results presented in Tables II and III 
demonstrated significant statistical difference between the 
control and the treatment groups. This was noted at both the 
100 I.U. contamination level (~ = 0.00108) and the 1 I.U. 
contamination level (~ c 0.00866). In Tables VI and VII, the 
efficacy tests' results using large volume parenteral solu-
tions showed significant difference between the contrpl and 
the test treatment groups. This occurred at the contamination 
levels of 100 I.U. (~ = 0.000078) and l I.U. (~ = 0.017093). 
Thus, the efficacy of the test method for both small and 
large volume parenteral solutions was established. 
The efficiency of the test method at contamination levels 
of 100 l.U. and 1 I.U. of TMV in small and large volume paren-
teral solutions was shown. Tables IV, V, VIII,·and IX sum-
marize this evidence. In the preliminary test and test con-
trol groups, incidental TMV contamination was not detected 
using the test methodology. Whereas in these same treatment 
groups, contamin~ted with 100 or 1 I.U. of TMV per ml of 
solution, TMV contamination was demonstrated by use of the 
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test methodology. For the preliminary tests with small 
volume parenteral solutio ns, statistically significant dif-
ference was observed between the control and treatment groups 
for the 100 I.U. level <R = 0.00108) and the 1 I.U. level 
(P = 0.00866). The tests using large volume parenteral solu-
tions showed significant difference between the control and 
test groups. Efficiency of the test methodology for a TMV 
contamination level of 100 I.U. (~: 0.000018) and 1 I.U. 
<R = 0.017093) ~as demonstrated. The electron micrographs 
illustrated j_n Figures 3, 4, 6 , and 7 describe the relative 
proportion of TMV occurrence as detected at 100 I.U. compared 
with the 1 I.U. level. Figures 3 and 6 show th e characteris-
tic clusters of many viruses usually observed at the 100 I.U. 
contaminatio n level . At a contamination level of 1 I.U. of 
TMV per ml of solution, singly occurring TP!V were us ua J.l y 
de t ected . These results are typifie d in Figures 4 and 7. 
SUM~tARY 
1. A survey of the lit e rature on parent e ra l contami-
nants, methods of parenteral contaminant detection, viral 
co ntamin ation of parente rals, and methods of viral conce n-
tration was presented. In this literature revi ew, no r efer-
e nce was found describing viral contamination of pare nt e rals 
or a method for detectin g viral contaminants in pare nt e ral 
solutions. 
2 . A method was develope d for dete!mining the presence 
6f viruses in small volume as well as bulk parenteral s. Th e 
following methods and procedures were used to attain this 
obj e ctive: 
a. d~fined volumes of Sodium Chloride Injectjon 
U.S.P. and 5 percent Dext rose Injection U.S.P. 
we r e inoculated with 100 I . U. or 1 I.U. of 
Tobacc~ Mosaic Virus ; 
b. the conte nts of the parenterals were conce n-
trated to a retentate volume using mol ecul ar 
filtration; 
c. the ret e nt ate volume was examined for vira l 
content using transmission electron microscopy 
with negat ive staining techniques; 
d. the t est method was evaluated for its efficacy 
and efficiency through analysis of th e data 
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by the Fisher exact probabil i ty t est. 
3. The r esults showed that the defined method of viral 
detection i s efficacious and efficient at the tested TMV 
contami n a tion. levels for both s mall and large volume par en -
t eral soluti.ons. 
CONCLUSIONS 
A research method was develope d for determining the · 
presence of viruse s in small volume as well as bulk parenteral 
solutions. The results of this experimentation s howed that 
the def ined method of viral detection is efficacious and ef-
fici ent at the test e d TMV contamination levels . This test 
me thod could probably be utilize d for the de t ection of other 
virai contaminants of parenteral solutions. Furthermore, the 
ret e ntate volume, collected after the _concentration procedure 
in the test methodology, may b e readily adapted to animal, 
egg, or cell-culture inoculation for viral infe ctivity analy-
sis . 
The tes t method may b e classified as a destructive 
method of contaminant detect ion in parentera ls since the con-
tent s of the parenteral must be removed from the contaj_ ner 
for examination . The me thod does r equire careful attention 
to the protoco l and can b e tedious . These disadvant ages are 
inhe r e nt. 
This t est me tho d is a direct method of viral contaminant 
det ection and is a relative ly rapid process after the initial 
materj.a l and equipment preparation. The information acquired 
may be the most significant advantage t o be realized hy us e 
of the t est me thodolo gy. 
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The test methodology might find u se at · various levels in 
the parente ral ·solution de livery s ystem. Pare nteral manu-
factu rers could use this method to evaluate their products 
for the absenc e of virus at defined viral limits . Analysis 
of parenteral infusions for viral content might find use in 
hospitals for the evaluat ion of "in use" standards or monitor-
ing of admixture techniques. 
The expense of producing· and administerj_ng a sterile , 
nonpyrogenic, and viral-free infusion could be justified for 
immunologically incompetent pati e nt s. Similarly, the expense 
incurred in developing a viral r e t entive inline final filter 
could be justified. 
Future studies usi ng this method or other more effective 
~nd effj.clent met hods s hould be und e rtaken to ·pursue the 
assurance of viral--free parenteral solutio ns for improved 
health care . 
BI BL I OGRAPHY 
1. J. M. Garvan and B. W. Gunner, Med. J . Australia, ~~ 
140(1963). 
2. Ibid.;~-· 1(1964). 
3. J . M. Garvan and B. W. Gunner, Br . J. Clin. Pract., ~~. 
119( 1971). 
4. N . tL Davis, S. Turco, E. S i vel l y, Am. J . llosp . Pharm . , 
27) 822( 1970) . 
5. M. A. Gross and C. J. Carter, in "Symposium on Safety 
of Large Vol ume Parenteral Solutions, '' National Symposium 
P r oceedings, Food and Drug Adminfstration, Washington, 
D.C., 1966, p. 31. 
6 . J . D . Loekhart, i n "Symposium on Safety of Large 
Volume Parenteral Solutions,n National Symposium Pro-
ceedings, Food and Drug Administration, Washington, D. C., 
1966, p. 28. 
7. M. A. Gro~s, Drug Intell., !, 12(1967) . 
8 . W. C . Von Glahn a nd J. W. Hall, Am. J . Pathol., 25, 
575( 1949). 
9 . B. E . Konwa.ler, Am . J. Clin. Pathol., 20, 385(1950) . 
10 . C . J. Endicott, R . Giles, R. Pecina, in "Symposium on 
Safety of Large Volume Parenteral So l utions,'' National 
Symposium Proceedings, Food and Drug Administration, 
Washington, D.C., 1966, p . 62. 
11. M. Yakowitz, in nsymposium on Safety of Large Volume 
Paren teral Solutions,' ' National Symposium Proceedin gs , 
Food and Drug Administration, Washington, D.C., 1966 , 
p . 3. 
12. A. M. Jonas, in nsymposium on Safety o.f Large Volume 
Parente ral Solutions,'' National Symposium Proceedin gs , 




13. S . Sarrut, and C. Neze 1of, Presse Med. , §8, 375( 1960) . 
14. E. J. Bruriing, Virchow Pathol. Anat. Physio1. K1in. 
Med., 327, 468(1955). 
15. S. Turco and N.M. Davis, Hosp. Pharm., ~. 137(1973). 
16. P. B. Ryan, R. P. Happ, P. P. DeLuca, W. 0. Griffen, 
J.D. Clark, D. Cloys, Bull. Parenter. ·Drug Assoc., 
2~, 1(1973). 
17. P. P. DeLuca, R. P. Rapp, B. Bivins, H. E. McKean, 
W. 0 . Giffen, Am . • L Hosp. Pharm., 32, 1001(1975) . 
18. R. S. Levinson, L. V. Allen, W. F. Stanaszek , W. F., 
S. ~Iills, Am. J. Hosp. Pharm., 32, 1137(1975). 
19. ~. Raviri, J. Bahr, F. Luscomb, J. Gooch, S . Mutter , 
. S. D. Spi ttel, Am. J. Hosp. Pharm. , _:g_, 34 0( 1974). 
20. D. M. Poretz, J. B. Guynn, R. J. Duma, H. P . Dalton, 
Am .. J. Hosp. Pharm., ~. 726(1974). · 
21. A. L. Hanson and R. M. Shelley, Am. J . Hosp. Pharm ., ~!, 
733(1974). 
22. R. J. Durna,· N . Engl. J. Med., 29,:!, 1178(1.9'16) . 
23. T. Rebagay, R. Rapp, B. Bivins, P. P. DeLuca, Am . J. 
Hosp. Pharm., .33, 433 (1976). 
24. T. Rebagay and P. P. DeLuca, Am. J. Hosp . Pharm . , ~~, 
443(1976). 
25. N. S . Jaffe, Bull. Pa renter. Drug Assoc ., 24, 218(1970). 
26 . J. E. Dimmick, K. E. Bove, A. J. Mc Adams, G. Benzing, 
N. Engl. J. Me d . , 292, 685(1975) . 
27. W. B . Wartman, R. B. J e nnings , B. Hudson, Circulat i on, i. 
747(1951). 
28. W. E. Stehbens a nd H. W. Florey, Quart. J. Exp . Physiol ., 
45, 252(1960) . 
29 . J. Y. Masuda and J. H. Beckerman, Am. J. Hosp . Pharm . , 
·30, 72(1973). 
30. Ibid., l!_ , 1189(1974). 
65 
31. National Coordinating Committee on Large Volume Paren-
terals, Am . J. Hasp. Pharm., 32, 261(1975). 
32. H. F. Hammer, Bull. Parenter. Drug Assoc., 28, 205(1974). 
33. S. J. Turco, Bull. Parenter. Drug Assoc., 28, 197(1974). 
34. S. J. Turco and N. M. Davis, Bull. Parenter. Drug Assoc., 
27' 207(1973). 
35. J. B. Guynn, D. M. Poretz, R. J. Duma, Am . J. Hasp . 
Pharm., 3Q, 321(1973). 
36. J. S. Hansen and C. D. Hepler, Am . J. Hosp. Pharm ., 
30, 326(1973). 
37. W. A. Zellmer, Am. J. Hasp. Pharm. , ~~.' 255( 1975). 
38. S. Rusml.n, M. B. Althauser, P. P. DeLuca, Am. J. Hasp. 
Ph arm . , 3 2 , 3 7 3 ( 19 7 5 ) . 
39. S. Rusm].n and P. P. DeLuca, Am. J. Hasp. Pharm., 32, 
378(1975). 
40. R. C. Huber and C. Riffkin, Am. J. Hasp . Pharm ., _32, 
173(1975). 
41. National Coordinating Commit tee on Large Vo lume Pa r e n--
terals, Am. J. Hasp . Pharm ., 32, 1251(1975). 
42. R. Rapp, B. Vivins, H. Schroeder, P. P. DeLuca, ~n. J. 
Hasp. Pharm., 32, 1253(1975). 
43. J. Blanchard, C. M. Thompson, J. A. Schwartz, . Am . J . 
Hasp . Pharm ., 33, 144(1976). 
44. National Coordinating Committee on Large Volume Paren-
terals, Am. J . Hosp. Pharm., 33, 231(1976). 
45. K. N. Barker, Bull. Parenter . Drug Assoc., 27, 178( 1973). 
46. R. G. Draft z and J. Graf , Bull . Parenter . Drug Assoc., 
_2 8 ' 3 5 ( 19 7 4 ) . 
47. R. J. Lantz, E. G. Shami, L. Lachman, Bull. Par enter . 
Drug . Assoc ., 30, 234(1976) . 
48. A. L. Notkins and H. Koprowski , Sci . American, 228, 
22(1973) . 
49. J. J. Holland, Sci . American, 230, 32(1974) . 
66 
50. K. N. B~.rker, in ''Ha ndbook of I.V. Additive Re views 
1973," D. E. Franc.ke , Ed., Drug Intelligence Publica-
tions, Hamilton, Il., 1973, p. 1. 
51. S . D. Steckel, M. Gonik, P. J. Martens, J. A. Patel, 
E. G . . Curtis, N. F. H. Ho, in "Handbook of I.V. Additive 
Reviews 1973," D. E. Francke, Ed., Drug Intelligence 
Publications, Hamilton, Il., 1973, p. 17. 
52. W. R. Wilkinson, L. L. Flores, J. N. Pagones, in 
"Handbook of I.V. Additive Reviews 1973," D. E . Francke, 
Ed., Drug Int e llj gence Publications, Hamilton, Il., 
1973, p . 29. 
53. P. G. Pierpaoli, H. A. Palmer, R. J. Codino, in 
"Handbook of· I. V. Additive Reviews 1973, 11 D. E. Francke, 
Ed. , Drug Intelligence Publications, Hamil ton, I l. , 
1973, p . 33. 
54. L. Ernerot, S. Thoren, E. Sandell, in· "Handbook of I. V. 
Additive Reviews 1973," D. E. Francke, Ed., Drug 
Intelligence Publications, Hamilton, Il., 1973, p. 55. 
55. T. H. But l er and R. E. Pluhar, in nHandhook of I.V. 
Additive Reviews 1973," D. E. Francke, Ed., Drug Int e l -
ligence Publications, Hamilton, Il. , 1973, p . 45. 
56. I. Vessey and C . E. Kendall, Analyst, Q!_, 273(1966 ). 
57. Y. S. Lim~ S. Turco, N. M. Davis, Am. J. Hos p. Pha rm., 
_30, 518(1973) . 
58. E~ N. Deeb and G. A. Natsios, Am. J . Hosp . Pha rm., 
28' 764( 1971). 
59. Anon. , Can ad. J. Hosp. Pharm. , 24, 226( 1971). 
60. R. J. Duma, J. F. Warne r, H. P. Dalton, N. Engl . J . 
Med., 284, 257(1971). 
61. M. R. Hales, Am. J. Pathol., 5, 927(1956). 
62. A. A. Liebow, M. R. Hales, G. E. Lindskog, Am . J. 
Pathol., ~. 211(1949). 
63. C. R. Curry and P . G. Quie, N. Engl. J. Med., 285, 
1221(1971). 
64. "Sympos ium on Sa f e ty of Large Volume Pare nte r a l s ·olu -
tions," Nationa l Symposium Proceedings, Food and Drug 
Admj.ni s tration, Washington, D.C., 1966. 
67 
65. R. J. Duma, Ann. Int. Med., 1~. 146(1973). 
66. J. J. Piecoro, N. L. Goodman, W. E. Wheeler, P. R. Gwilt, 
R. ·P. Rapp, Am. J. Hasp. Pharm., 32, 381(1975). 
67. S. Levine, in "Symposium on Safety of Large Volume 
Parenteral Solutions," National Symposium Proceedings, 
Food and Drug Administration, Washington, D.C., 1966, 
p. 71. 
68. C. J. Dawes, "Biological Techniques in Electron ~fl. eros-
copy," Barnes a.nd Noble, Inc. , New York, N.Y . , 1971, p. 1. 
69. N. F. llo, R. L. Church, H. Lee, Drug Intell. , !. 
356(1967). 
70. Personal communication: J. D. Theis, Marketing J,ianager, 
Royce Instruments, Inc., Menlo Park, Ca. , 1975. 
71. Anon., "TT MC Particle Measurement Computer System," 
Millipore Corporation, Bedford, Mass . , 1972 . 
72. Anon., in ... The United States Pharmacopeia, 19th H.ev i--
sion, 1st Supplement," The United States Pharmacope ia! 
Convention, Inc., Rockville , MaryJ.and, Apr. 29, 1976, 
p. 56. 
73. G. '1' . St(~v:art, Ant imicrob. Agents Chorilothe r. , 19B_I, 
543( 1967). 
74. R. II. Haschemeyer and R. J. Myers, in "Principles and 
Techniques of Electron Microscopy, Biological Applica-
tl.ons," Vol. 2, M. A. Hayat, Ed., Van Nostra nd Reinhold 
Co., New York, N.Y., 1972, pp. 101 - 147. 
75. R. ·w. Horne, A. P. Waterson, P. Wildy, A. E. Farnh~m, 
Virology, ~~. 79(1960). 
76. L. Hoyle, R. W. Horn e , A. P. Waterson, Virology, 11_, 
448(1961) . 
77. D. H. Watson, in "Fifth International Congress for 
·Electron Microscopy, " S. S. Breese, Ed. , Academte Press 
Inc. , New York, N.Y., 1962, pp. X-4. 
78. D. G. Sharp, in "Proceedings of the Fourth International 
Conference on Electron Microscopy," Berlin,. 1958, 
pp. 542 - 548. 
79. S. Brenner and R. W. Horne , Btochim. Biophys . Acta, 
-~'! , 1 0 3 ( 19 59 ) . 
68 
80. K. 0. Smith and J. L. Melnick, Virology , 17, 480(1962). 
81. D. H. Watson, W. C. Russe ll , P. Wildy, Virology, 19, 
250( 1963). 
82. R. W. Horne and P. Wildy, Brit. Med . Bull., 18, 
199(1962). 
83. D. H. Watson, Biochim. Bio"phys. Acta, ~n, 321(1962). 
84. R. W. Horne and P. Wildy, . Virology, .!.~. . 348( 1961). 
85 . R. W. Horne, in "Me thods in VJ.rolcgy, 11 Ve l. III, 
K. Maramorosch and H. Koprowski, Ed ., Academic Press , 
New York, N.Y. , 1967, pp. 521 - 574. 
86. R. Markham, in "Methods in Virology , " Vol. II, K. Mara-
morosch and H. Koprowski, Ed., Academic Press, New York, 
N.Y., 1967, pp . 1 - 39. 
87. H. M. Mazzone, in "Methods in Virology, " Vol. II, 
K. Mararnorosch and H. Koprows ki, Ed .. , Academic Press, 
New York, N.Y., 1967, pp. 41 - 86. 
88. M. K. pra.kke, in "Methods in Virology," Vol. J:I, 
K. Maramorosch and H. Kaprowski, Ed. , Acadernj c Press, 
New York, N.Y., 1967, pp. 93 - 117. 
89. N. G. Anderson ~. nd G. B. Cl:ine, in "Methods in Virology ," 
Vol. II, K. Maramorosch and H. Kaprowski, Ed . , Aca demic 
Press, New York, N.Y., 1967, pp. 137 - 177. 
90. I\. Strohmaier, in "Methods in Virology, " Vol. II, 
K. Maramorosch and H. Kaprowski, Ed., Academi.c Press, 
New York, N.Y., 1967, pp. 245 - 274. 
91. V. P. ·Perry and ~L M. Vincent, in "Methods in Virology, ' ' 
Vol. II, K. Mararnorosch and H. Kaprowski, Ed., Academic 
Press, New York, N.Y., 1967, pp. 367 - 389. 
92. L. Philipson, in "Methods in Virology," Vol. II, 
K. Maramorosch and H. Kaprowski, Ed., Academic Press, 
New · !crk, N.Y., 1967, pp; 179- 230. 
· 93. G. K. Ackers and R. L. Steere, in "Methods in Virology,'' 
Vol. I I, K. Maramorosch and H. Kaprowski, Ed., Academic 
Press , New York, N.Y., 1967, pp. 325 - 364. 
94. A. Polson and B. Russell, in "Methods in Virology," 
Vol. II, K. Maramoros ch and H. Kaprowski, Ed., Academic 
Press , New York, N.Y., 1967, pp . 391 - 425 . 
95. M. K. Brakke, in "Methods in Virology," Vol . II, 
K. Maramorosch and H. Kaprowski, Ed., Academic Press, 
New York, _N.Y., 1967 , pp. 119- 135 . 
96. R. W. Horne and P. Wildy, in "Advances in Virus Re-
search," Vol. 10, K. M. Smith and M. A. Lauffer, Ed . , 
Academic Press, New York , N.Y., 1963, pp. 101 - 170. 
97. R. C. Valentine, in "Advances in Virus Researc.h," 
Vol. 8, K. M. Smith and M. A. Lauffer, Ed., Academic 
Press, New York, N.Y., 1961, pp. 287 - 318. 
98. J . D. Acton, L. S. Kucera, Q. N. Myrvik, R. S. Weiser, 
"Fundamentals of Medical Virology , " Lea and r'ebiger, 
Philadelphia, Pa., 1974, . pp. 7 - 15. 
99. Anon., The Nation's Health,! , l(July 1974) . 
100. Anon., ASM News (American Society for f1ic robiology ), 
41, 52 ( 197 5) . 
101 . C. P. Gerba, C . Wallis, J. L. Melnick, Environ. Sci. 
Tech ., ~, 1122(1975). 
102 . F. B. Taylor, J. Am. Water Works Assn., 6§_, 306(1974). 
103. J. E . Herrm~nn, K. D. Ko s tenbader Jr., D .. 0. Cliver, 
App l. Micr0 . , 28, 895(1974) . 
104. W. F. Hill Jr., E. W. Akin, W. H. Benton, T. G. Metcalf, 
Appl. Mic1~0. , 23, 880( 1972) 
105. J. A. Bryan, J. D. Lehmann, 1. F . Setiady, M. H. Hatch, 
Am. J. Epidem., Q~, 145(1974) . 
106. F . . A. Denis, E . Blanchouin, A. DeLignie res, P. F1amen, 
J. Am. Me d . Assoc . , 228, 1370(1974). 
107 . F. G. Bieberly Jr. a nd H. D. Anthony, Kansas Acad . 
. Sci. Trans. , 68, ?.69( Aug. 1965). 
108. Anon., "Molecular Fi1 tration," Mill.ipore Corporation, 
Bedford, Mass ., 1974. 
109. 0. Winding and B. Ho1ma, Am. J. Hosp. Pharrn., _?3, 
1154( 1976) . 






111. G. Berg, H. L. Bodily, E. H. Lennette, J. L. Melnick, 
T. G. Metcalf, "Viruses in Water," American Public 
Health Association, Inc., Washington, D.C., 1976. 
112. Personal communication: R. Ka1onowski and R. Oji, 
Federal Food and Drug Administration, San Francisco, 
Ca., 1978. 
113. S. Gard and 0. Maa1oe, in "The Viruses, Geueral Vi.rology," 
Vol. 1, F. M. Burnet and W. M. Stanley, Ed., Academic 
Press, New York, N.Y., 1959, pp. 359- 427. 
114. Personal communication: T. Shalla, Dept. Plant Pathology, 
University of California, Davis, Ca., 1977. 
115. H. Fraenkel-Conrat, in "The Viruses, General Virology," 
Vol. l, F. M. Burnet and W. M. Stanley, Ed., Academic 
Press, New York, N.Y., 1959, pp. 429- 457. 
116. R. Dulbecco and H. S. Ginsberg, in "Microbiology," 
B. D. Davis, R. Dulbecco, H. N. Eisen, H. S. Ginsberg, 
W. B. Wood Jr., and M. McCarty, 2nd Ed., Harper and 
Row, Publishers, Inc., Hagerstown, Md., 1973, p. 1041. 
117. S. Siegel, "Nonparametric Statistics for the Behavioral 
ScienceE;," McGraw-Hill Book Co., Inc., New York, N.Y., 
1956, pp. 96 - 104. 
118. "The United States Pharmacopeia," lBth Revisi.on, Mack 
Publishing Co., Easton, Pa., 1970, p. 976. 
119. C. E. Bricker and H. R. Johnson, Ind. Eng. Chem., Anal. 
Ed., U, 400(1945). 
120. Anon., "Immersi.ble Molecular Separator Kit Op-eration and 
Maintenance," Millipore Corporation, Bedford, Mass., 
1975, p. 17. 
